Journal
CLINICAL RHEUMATOLOGY
Volume 26, Issue 8, Pages 1344-1345Publisher
SPRINGER
DOI: 10.1007/s10067-006-0356-5
Keywords
etanercept; rheumatoid arthritis; TNF-alpha antagonists; visceral leishmaniasis
Categories
Ask authors/readers for more resources
Visceral leishmaniasis (VL) is a severe disease that can develop in immunocompromised patients. Antitumor necrosis factor-alpha (TNF-alpha) treatment of rheumatoid arthritis can result in clinical benefits, but with an increased risk of opportunistic infections. Leishmania infection in patients treated with TNF-alpha antagonists is extremely rare; for this reason, we report a patient with VL after etanercept treatment who had an unfavorable outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available